New report explores traditional, specialty therapy trend impact to employers

March 27, 2026 – vanzacaftor/tezacaftor/deutivacaftor (Alyftrek) Vertex; combination of deutivacaftor (a CFTR potentiator) and tezacaftor/vanzacaftor (CFTR correctors); expanded indication is based...

The Fall 2025 Prime Therapeutics Report delivers a comprehensive look at the evolving oncology landscape—from rising cancer rates in younger populations to the expanding role of...

Cover image for The evolution of GLP-1s Developing a holistic, individualized strategy to capitalize on opportunities and outcomes Prime Therapeutics /the-evolution-of-glp-1s About Prime...

This monthly approval update provides a review of newly approved specialty drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

July 14, 2025 Author: Abby Kim, PharmD, BCOP The DESTINY-Breast09 trial marked a pivotal moment in the treatment of HER2-positive metastatic breast cancer, offering the first major advancement in...

The Prime Therapeutics Report is your trusted source for the latest in managed care strategies, specialty drug trends and payer-focused insights. The Summer 2025 issue features a cover story on HIV...

The American Thoracic Society, CDC, European Respiratory Society and Infectious Diseases Society of America (IDSA) have published updated clinical practice guidelines for tuberculosis (TB)...